Synergistic compositions and use of same for appetite suppression and muscle preservation

A synergistic composition of N-acetyltaurine and taurine addresses muscle loss during weight loss and weight regain post-GLP-1 therapy by enhancing appetite suppression and muscle preservation, achieving effective weight management with reduced side effects.

WO2026239387A1PCT designated stage Publication Date: 2026-11-19METABOLIZE INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2026/050402
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current weight loss strategies often result in unintended muscle loss, and GLP-1 receptor agonist therapy discontinuation leads to significant weight regain, highlighting the need for compositions that suppress appetite and preserve muscle mass.

Method used

A synergistic composition comprising N-acetyltaurine (NAT) and taurine, which modulates appetite regulation and muscle metabolism through enzymatic conversion pathways, providing prolonged appetite suppression and muscle preservation effects.

Benefits of technology

The combination of NAT and taurine enhances appetite suppression and muscle preservation, maintaining lean muscle mass during weight loss, and reduces hepatic fat accumulation, while potentially reducing the weight regain associated with GLP-1 receptor agonist discontinuation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IL2026050402_19112026_PF_FP_ABST
    Figure IL2026050402_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention is directed to a composition including a taurine derivative, such as N-acetyltaurine (NAT) and taurine. Further provided are methods including administering the composition to a subject in need thereof, such as for suppressing appetite and preserving muscle during weight loss, treating sarcopenia or ameliorating at least one symptom associated therewith, treating or preventing insulin resistance, prolonging the appetite-suppressing effect of a taurine derivative, managing weight regain following discontinuation of a GLP-1 receptor agonist therapy, augmenting weight loss while being treated with a GLP-1 receptor agonist, or treating or preventing muscle loss during weight loss, in a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] SYNERGISTIC COMPOSITIONS AND USE OF SAME FOR APPETITE SUPPRESSION AND MUSCLE PRESERVATION

[0002] CROSS REFERENCE TO RELATED APPLICATIONS

[0003]

[0001] This application claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 804,693, entitled "SYNERGISTIC COMPOSITIONS AND USE OF SAME FOR APPETITE SUPPRESSION AND MUSCLE PRESERVATION", filed May 13, 2025, the contents of which are incorporated herein by reference in their entirety.

[0004] FIELD OF INVENTION

[0005]

[0002] The present disclosure relates to compositions for weight loss and appetite suppression, and more particularly to a composition comprising N-acetyltaurine and taurine for muscle-sparing appetite suppression and weight loss. The disclosure further relates to methods for co-administration with GLP-1 receptor agonists, methods for managing weight regain following discontinuation of GLP-1 receptor agonist therapy, and methods for reducing hepatic fat accumulation.

[0006] BACKGROUND

[0007]

[0003] Weight management is a significant health concern for many individuals worldwide. As obesity rates continue to rise, there is an increasing focus on developing effective strategies for weight loss and appetite control. However, weight loss often comes with unintended consequences, particularly the loss of lean muscle mass alongside fat reduction.

[0008]

[0004] Muscle preservation during weight loss is crucial for maintaining overall health, metabolic function, and physical performance. When individuals lose weight, especially through calorie restriction or certain pharmacological interventions, they may experience a reduction in both fat and muscle tissue. This loss of muscle mass can have detrimental effects on metabolism, strength, and long-term weight maintenance.

[0009]

[0005] Various approaches have been explored to address the challenge of preserving muscle mass during weight loss. These include high-protein diets, resistance trainingprograms, and nutritional supplements. Each of these strategies aims to support muscle protein synthesis and minimize muscle breakdown during periods of caloric deficit.

[0010]

[0006] In recent years, there has been growing interest in the role of specific amino acids and their derivatives in appetite regulation and muscle metabolism. Taurine, a sulfur-containing amino acid, has been studied for its potential benefits in muscle function and preservation. Additionally, researchers have begun investigating related compounds that may have synergistic effects on appetite control and muscle maintenance.

[0011]

[0007] As the field of weight management continues to evolve, there is an ongoing need for innovative approaches that can effectively support weight loss while simultaneously preserving lean muscle mass. Such solutions could potentially offer improved outcomes for individuals seeking to manage their weight and maintain overall health and fitness.

[0012]

[0008] The development of new compositions and methods for appetite suppression and muscle preservation represents an active area of research. Advancements in this field have the potential to address some of the limitations associated with current weight loss strategies and provide more comprehensive solutions for individuals struggling with weight management

[0013]

[0009] GLP-1 receptor agonists, such as semaglutide and tirzepatide, have demonstrated significant efficacy for weight loss in clinical trials. However, clinical data from the STEP 4 and SURMOUNT-4 trials have revealed a substantial challenge: patients who discontinue GLP-1 receptor agonist therapy experience significant weight regain, often recovering two-thirds or more of the weight lost during treatment within one year of discontinuation. This weight regain phenomenon represents a significant unmet clinical need and highlights the importance of developing complementaiy or alternative approaches that may support weight maintenance following GLP-1 therapy discontinuation or augment weight loss during GLP-1 therapy while preserving lean muscle mass.

[0014]

[0010] Recent research has identified N-acetyltaurine (NAT) as an endogenous metabolite with appetite-suppressing properties. NAT is hydrolyzed by the enzyme phosphotriesterase-related protein (PTER) to yield taurine and acetate. The discovery of this metabolic pathway, including the bidirectional nature of the PTER-catalyzedreaction, provides a scientific foundation for developing compositions that may modulate NAT levels and thereby influence appetite regulation and metabolic function.

[0015] SUMMARY

[0016] [Oil] This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summaiy is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.

[0017]

[0012] According to the first aspect, there is provided a composition, comprising a synergistically effective amount of taurine derivative and taurine.

[0018]

[0013] According to another aspect, there is provided a method for suppressing appetite and preserving muscle during weight loss in a subject in need thereof, the method comprising administering to a subject a composition comprising taurine derivative and taurine, thereby suppressing appetite and preserving muscle during weight loss in the subject.

[0019]

[0014] According to another aspect, there is provided a method for treating sarcopenia or ameliorating at least one symptom associated therewith in a subject in need thereof, the method comprising administering to a subject a composition comprising taurine derivative and taurine, thereby treating sarcopenia or ameliorating at least one symptom associated therewith in the subject

[0020]

[0015] According to another aspect, there is provided a method for treating or preventing insulin resistance in a subject in need thereof, the method comprising administering to a subject a composition comprising taurine derivative and taurine, thereby treating or preventing insulin resistance in the subject

[0021]

[0016] According to another aspect, there is provided a method for prolonging the appetite-suppressing effect of a taurine derivative in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising taurine and a taurine derivative.

[0022]

[0017] According to another aspect, there is provided a method for managing weight regain following discontinuation of a GLP-1 receptor agonist therapy in a subject in needthereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a taurine derivative and taurine.

[0023]

[0018] According to another aspect, there is provided a method for augmenting weight loss while being treated with a GLP-1 receptor agonist in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a taurine derivative and taurine.

[0024]

[0019] According to another aspect, there is provided a method for treating or preventing muscle sparing weight loss in a subject being subject treated with a GLP-1 receptor agonist, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a taurine derivative and taurine.

[0025]

[0020] According to another aspect, there is provided a method for reducing hepatic fat accumulation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a taurine derivative and taurine.

[0026]

[0021] According to another aspect, there is provided a method for treating or preventing metabolic dysfunction-associated steatotic liver disease (MASLD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a taurine derivative and taurine.

[0027]

[0022] According to another aspect, there is provided a method for prolonging the halflife of N-acetyltaurine in a subject, the method comprising administering to the subject an effective amount of taurine.

[0028]

[0023] In some embodiments, the composition is administered in a dosage of 250 to 1,000 mg NAT and 250 to 2,000 mg taurine twice daily.

[0029]

[0024] In some embodiments, the composition is administered in a dosage of 400 to 600 mg NAT and 800 to 1,000 mg taurine twice daily.

[0030]

[0025] In some embodiments, a first administration is with a breakfast meal, and a second administration is with an evening meal.

[0031]

[0026] In some embodiments, the composition is characterized by a prolonged appetitesuppressing effect of the taurine derivative.

[0027] In some embodiments, the composition is characterized by enhanced efficacy of the taurine derivative for appetite suppression compared to the taurine derivative alone.

[0032]

[0028] In some embodiments, the composition is characterized by supporting lean muscle mass preservation during weight loss.

[0033]

[0029] In some embodiments, the composition is used in a method for appetite suppression and muscle preservation during weight loss in a subject administered therewith.

[0034]

[0030] In some embodiments, the subject is administered with a total daily taurine amount of 1.5-4 grams.

[0035]

[0031] In some embodiments, administered is with a reduced dosage of the taurine derivative compared to the administration taurine derivative alone.

[0036]

[0032] In some embodiments, the taurine derivative comprises N- Acetyltaurine (NAT).

[0037]

[0033] In some embodiments, the composition further comprises beta hydroxybutyrate (BHB) conjugated to phenylalanine (BHB-Phe)

[0038]

[0034] In some embodiments, a muscle is lean muscle.

[0039]

[0035] In some embodiments, treating comprises restoring glucose homoeostatic levels in the subject

[0040]

[0036] In some embodiments, administering is in a dosage ranging between 250 and 1,000 mg the taurine derivative and ranging between 250 and 2,000 mg taurine, twice daily.

[0041]

[0037] In some embodiments, the administering is in a dosage ranging between 250 and 1,000 mg of the taurine derivative and ranging between 250 and 2,000 mg taurine, twice daily.

[0042]

[0038] In some embodiments, the administering is in a dosage ranging between 400 and 600 mg of the taurine derivative and 800 to 1,000 mg taurine, twice daily.

[0043]

[0039] In some embodiments, administering is at a total daily taurine amount ranging between 1.5 and 4 grams.

[0040] In some embodiments, administering is at a reduced dosage of the taurine derivative compared to the taurine derivative being administered alone.

[0044]

[0041] In some embodiments, suppressing appetite and preserving muscle duringweight loss comprises prolonging an appetite-suppressing effect of the taurine derivative.

[0045]

[0042] In some embodiments, the composition is characterized by enhanced efficacy of the taurine derivative for appetite suppression compared to administration of the taurine derivative alone.

[0046]

[0043] In some embodiments, the composition further comprises a branched chain amino acid (BCAA), Hydroxy beta-methyl butyric acid (hmb), creatinine, or any combination thereof.

[0047]

[0044] In some embodiments, administering further comprises administering to the subject a therapeutically effective amount of an anti-obesity drug.

[0048]

[0045] In some embodiments, the anti-obesity drug comprises a GLP-1 agonist.

[0049]

[0046] In some embodiments, the anti-obesity drug is selected from the group consisting of: semaglutide, orlistat, metformin, and any combination thereof.

[0050]

[0047] In some embodiments, the composition and the anti-obesity drug are coadministered in a synergistically effective amount

[0051]

[0048] In some embodiments, any one of suppressing, treating, preventing, and ameliorating, comprises inhibiting phosphotriesterase-related enzyme (PTER)-mediated conversion of the taurine derivative, thereby prolonging an effect of the taurine derivative.

[0052]

[0049] In some embodiments, the effect is appetite-suppressing effect.

[0053]

[0050] In some embodiments, the appetite-suppressing effect of NAT comprises modulating enzymatic conversion of the taurine derivative by PTER in the subject.

[0054]

[0051] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as commonly understood by one of ordinaiy skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and / or materials are described below. In case of conflict, the patentspecification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

[0055]

[0052] Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

[0056] BRIEF DESCRIPTION OF THE DRAWINGS

[0057]

[0053] Fig. 1 includes a graph showing the in vivo effect of BHB-Phe, N- Acetyl taurine (NAT), BHB-Phe + NAT, and NAT + taurine combinations, in obese mice.

[0058]

[0054] Figs. 2A-2C include vertical bar graphs showing the effect of Vehicle, NAT, or NAT+taurine on metabolic blood markers. (2 A) Glucose; (2B) Triglycerides; and (2C) Cholesterol, p values for the difference between the vehicle left bar) to treatment right bars) are presented.

[0059]

[0055] Figs. 3A-3B include box plots showing muscle preservation under treatments with vehicle and NAT+taurine. (3A) A Grip strength / BW (End-Baseline); and (3B) A Hang Time / BW (End-Baseline).

[0060] DETAILED DESCRIPTION

[0061]

[0056] The following description sets forth exemplary aspects of the present disclosure. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure. Rather, the description also encompasses combinations and modifications to those exemplary aspects described herein.

[0062]

[0057] The present disclosure relates to compositions for appetite suppression and muscle preservation during weight loss. In some embodiments, the compositions include N- Acetyl taurine (NAT) and taurine. The compositions provide benefits for individuals seeking to lose weight while maintaining lean muscle mass. In some embodiments, the compositions address challenges associated with muscle loss during weight reduction, particularly when using appetite suppressants or following calorie-restricted diets. Thecompositions offer a novel approach to weight management by combining appetite suppression effects with muscle preservation properties. In some embodiments, the compositions provide synergistic benefits beyond what individual components offer alone. The compositions are formulated in various forms and are administered through different routes to suit individual needs and preferences.

[0063]

[0058] The present disclosure relates to compositions comprising N- Acetyltaurine (NAT) for appetite suppression and weight loss. NAT, also known as N-acetyl-2-aminoethanesulfonic acid, is a derivative of taurine with the chemical formula C4H9NO4S. NAT has a molecular weight of approximately 167.18 g / mol and exists as a white crystalline solid at room temperature.

[0064]

[0059] In some embodiments, NAT functions as an appetite suppressant by modulating neuronal pathways involved in hunger and satiety. The mechanism of action for NAT's appetite-suppressing effects involves interactions with neurotransmitter systems or hormonal signaling pathways related to food intake regulation.

[0065]

[0060] NAT is converted to taurine and acetate via the enzyme phosphotriesterase-related protein (PTER; EC 3.5.1. — ), a zinc-dependent amidohydrolase in the metallo-fl-lactamase superfamily. Published kinetic parameters for PTER include: Kcat = 2,600 s-1, Km(NAT) = 430 pM for forward hydrolysis; Km(taurine) = 64 mM and Km(acetate) = 11 mM for the reverse synthesis reaction; Keq = 0.117 M-l, favoring hydrolysis under basal conditions. This conversion process occurs in various tissues throughout the body, including the liver and brain. The rate of conversion varies depending on factors such as dosage, individual metabolism, and concurrent supplementation with other compounds.

[0066]

[0061] Without being bound by theory, the presence of exogenous taurine in a subject coadministered N-acetyltaurine prolongs the half-life of N-acetyltaurine in plasma and tissues through two complementary mechanisms operating on the PTER enzyme. First, taurine is a product of PTER-catalyzed hydrolysis of N-acetyltaurine; elevated taurine concentrations therefore inhibit the forward hydrolytic reaction through product inhibition, reducing the rate of N-acetyltaurine degradation. Second, because PTER catalyzes a thermodynamically reversible reaction (N-acetyltaurine + H2O taurine + acetate), elevated taurine and acetate concentrations shift the equilibrium toward N-acetyltaurine re-synthesis, providing a mechanism for continuous regeneration of theactive compound. Together, these effects constitute a pharmacokinetic extended-release mechanism whereby co-administered taurine reduces the net clearance rate of N-acetyltaurine, prolongs its plasma and tissue exposure, and thereby extends its appetitesuppressing activity through sustained GFRAL receptor engagement This mechanism is supported by Bliss Independence Synergy Analysis demonstrating that the observed combined effect exceeds the expected additive effect (Example 2).

[0067]

[0062] Supporting evidence for this mechanism is found in studies of PTER-knockout mice. In some studies, PTER-KO mice maintained on taurine-supplemented water showed significantly reduced body weight, food intake, and fat mass compared to wildtype controls, confirming that blocking PTER-mediated NAT degradation in the presence of taurine-driven NAT synthesis produces an anti-obesity phenotype. Published data from Wei etal. 2024 (Nature 633:182) demonstrated that taurine alone at 15 mg / kg / day IP produced no significant weight effect (p = NS versus vehicle), whereas the NAT+Taurine combination in the present studies achieved 88% weight gain reduction (Example 2).

[0068]

[0063] In some embodiments, the dosage of NAT for appetite suppression ranges from about 100 mg to about 2000 mg per day. For example, a composition contains 500 mg of NAT to be administered twice daily, resulting in a total daily dose of 1000 mg. This range is further divided into sub-ranges, including about 100 mgto about 500 mg per day, about 500 mgto about 1000 mg per day, about 1000 mgto about 1500 mg per day, about 1500 mg to about 2000 mg per day, about 250 mg to about 750 mg per day, about 750 mg to about 1250 mg per day, or about 1250 mg to about 1750 mg per day. Each possibility represents a separate embodiment of the invention. The specific dosage is adjusted based on factors such as body weight, age, and individual response to the compound. In some embodiments, dosage adjustments are made in increments of 50 mg, 100 mg, or 250 mg, depending on the individual's needs and response to treatment

[0069]

[0064] NAT is administered through various routes, including oral, sublingual, or parenteral. In some embodiments, oral administration is preferred for convenience and patient compliance. NAT is formulated into tablets, capsules, powders, or liquid solutions for oral consumption. For example, a composition includes 500 mg of NAT in a gelatin capsule for twice-daily administration.

[0065] The conversion of NAT to taurine via PTER results in a gradual release of taurine in the body. This process contributes to the muscle-sparing effects of the composition, as taurine is associated with muscle preservation during weight loss.

[0070]

[0066] In some embodiments, the composition is designed to optimize the conversion rate of NAT to taurine. For example, the composition includes additional compounds that modulate PTER activity or influence the pharmacokinetics of NAT. These modifications allow for tailored release profiles and enhanced bioavailability of both NAT and its metabolites.

[0071]

[0067] The composition includes taurine, an amino acid derivative that plays a role in various physiological processes. Taurine contributes to muscle preservation during weight loss and offers synergistic effects when combined with N- Acetyltaurine (NAT).

[0072]

[0068] The composition comprises a synergistically effective amount of N- Acetyltaurine (NAT) and Taurine. In some aspects, the synergistic combination of NAT and Taurine results in enhanced appetite suppression and muscle preservation effects compared to either compound alone (see Fig. 1). For example, in a 14-day study in diet-induced obese mice, NAT + Taurine achieved 88% weight gain reduction compared to 66-68% for NAT alone (Example 1). The synergistic effect allows for lower doses of each compound while maintaining or improving efficacy.

[0073]

[0069] In some embodiments, the synergistically effective amount ranges from about 250 mg to 1000 mg of NAT and about 250 mg to 1000 mg of Taurine per dose. This range is further divided into sub-ranges, including about 250 mg to about 500 mg of NAT and about 250 mg to about 500 mg of Taurine per dose, about 500 mg to about 750 mg of NAT and about 500 mg to about 750 mg of Taurine per dose, about 750 mg to about 1000 mg of NAT and about 750 mg to about 1000 mg of Taurine per dose, about 300 mg to about 600 mg of NAT and about 300 mg to about 600 mg of Taurine per dose, about 400 mg to about 800 mg of NAT and about 400 mg to about 800 mg of Taurine per dose, or about 600 mg to about 900 mg of NAT and about 600 mg to about 900 mg of Taurine per dose. The specific ratio of NAT to Taurine is optimized to achieve maximum synergistic effects. In some embodiments, various ratios are employed, including 1:1 ratio (e.g., 250 mg NAT : 250 mg Taurine), 2:1 ratio (e.g., 500 mg NAT : 250 mg Taurine), 1:2 ratio (e.g., 250 mg NAT : 500 mg Taurine), 3:2 ratio (e.g., 600 mg NAT : 400 mg Taurine), or 2:3 ratio (e.g.,400 mg NAT : 600 mg Taurine). Each possibility represents a separate embodiment of the invention. In some embodiments, the ratio is adjusted within a single dose or across multiple doses throughout the day to optimize the synergistic effects based on individual responses and metabolic factors.

[0074]

[0070] In some embodiments, NAT and Taurine are present in the composition in a weight per weight ratio (w / w) ranging between 10:1 and 1:10, 9:1 and 1:9, 8:1 and 1:8, 7:1 and 1:7, 6:1 and 1:6, 5:1 and 1:5, 4:1 and 1:4, 3:1 and 1:3, 2:1 and 1:2, or any ratio therebetween. Each possibility represents a separate embodiment of the invention.

[0075]

[0071] The synergistic combination results in prolonged appetite suppression due to the interaction between NAT and Taurine (see Fig. 1). In some aspects, the presence of Taurine slows the conversion of NAT via the phosphotriesterase-related (PTER) enzyme, extending the duration of NAT's appetite-suppressing effects. Bliss Independence Synergy Analysis confirms this synergy: with r(NAT) = 0.68 and r(Tau) « 0 (based on published literature), the expected combined effect r_exp = 0.68, while the observed effect r_obs = 0.88, yielding Ar = +0.20 (Example 2).

[0076]

[0072] The synergistically effective amount also enhances muscle preservation during weight loss (see Figs. 3A-3B). The combination of NAT and Taurine supports lean muscle mass retention more effectively than either compound alone. In some embodiments, this synergistic effect is due to improved protein synthesis, reduced muscle breakdown, or enhanced muscle cell hydration. Muscle grip strength and hang-time measurements in NAT+Taurine-treated subjects showed no significant decline versus vehicle controls, confirming muscle preservation during weight loss (Example 4).

[0077]

[0073] In some embodiments, the composition further comprises beta hydroxybutyrate (BHB). In some embodiments, the composition further comprises a hydrophobic amino acid. In some embodiments, the BHB is conjugated to the hydrophobic amino acid. In some embodiments, conjugated comprises or is bound to, e.g., a covalent bond. In some embodiments, hydrophobic amino acid is selected from: phenylalanine, leucine, isoleucine, valine, or any combination thereof. In some embodiments, the composition further comprises beta hydroxybutyrate (BHB) conjugated to a hydrophobic amino acid.

[0078]

[0074] In some embodiments, the hydrophobic amino acid is phenylalanine. In some embodiments, the composition further comprises BHB-Phe.

[0075] The composition is formulated to optimize the bioavailability and absorption of both NAT and Taurine, enhancing their synergistic effects. In some embodiments, the formulation includes specific excipients or delivery systems that promote the simultaneous absorption of both compounds. In some embodiments, the composition comprises ATA-Mg. In some embodiments, ATA-Mg is a magnesium salt of N-acetyltaurine. ATA-Mg is a preferred oral deliveiy form of NAT due to its superior bioavailability compared to free NAT acid. In some embodiments, ATA-Mg exhibits approximately 80% bioavailability compared to approximately 40-50% for free NAT acid, representing approximately a two-fold bioavailability advantage. This enhanced bioavailability allows for lower dosing while maintaining therapeutic efficacy. In some embodiments, a composition formulated to optimize the bioavailability and absorption of both NAT and Taurine comprises ATA-Mg.

[0079]

[0076] The synergistically effective amount of NAT and Taurine also results in improved metabolic outcomes (see Figs. 2A-2C). In some embodiments, the combination enhances insulin sensitivity, glucose metabolism, or lipid oxidation more effectively than either compound in isolation. For example, NAT+Taurine treatment resulted in glucose reduction of 30% (p = 0.009), triglyceride reduction of 25% (p = 0.001), and cholesterol reduction of 30% (p = 0.032) compared to vehicle controls (Example 3).

[0080]

[0077] The composition is designed to leverage the synergistic effects of NAT and Taurine across different timeframes. For example, the formulation provides immediate appetite suppression through NAT while supporting long-term muscle preservation through the sustained action of Taurine.

[0081]

[0078] In some embodiments, the synergistically effective amount is adjusted based on individual factors such as body weight, metabolic rate, or specific weight loss goals. The composition allows for personalized dosing to optimize the synergistic effects for each user.

[0082]

[0079] The synergistic combination of NAT and Taurine results in reduced side effects compared to higher doses of either compound alone. In some embodiments, this improves tolerability and adherence to the weight loss regimen.

[0080] According to another aspect, there is provided a combination comprising: NAT and Taurine. In some embodiments, NAT is formulated in a first composition. In some embodiments, Taurine is formulated in a second composition.

[0083]

[0081] In some embodiments, the combination is for use in suppressing or suppression of appetite and preserving or preservation of muscle during weight loss in a subject in need thereof.

[0084]

[0082] According to another embodiment, there is provided a combination of a first composition comprising an effective amount of NAT and a second composition comprising an effective amount of Taurine, for use in suppressing or suppression of appetite and preserving or preservation of muscle during weight loss in a subject in need thereof. In some embodiments, the effective amounts of NAT and Taurine obtain or provide a synergistic effect of suppressing or suppression of appetite and preserving or preservation of muscle during weight loss in a subject administered therewith.

[0085]

[0083] According to another embodiment, there is provided a (first) composition comprising an effective amount of NAT for use in enhancing the efficacy of Taurine. According to another embodiment, there is provided a (second) composition comprising an effective amount of Taurine for use in suppressing or suppression of appetite and preserving or preservation of muscle during weight loss in a subject administered with NAT.

[0086]

[0084] According to another embodiment, there is provided a (second) composition comprising an effective amount of Taurine for use in enhancing the efficacy of NAT. According to another embodiment, there is provided a (first) composition comprising an effective amount of NAT for use in suppressing or suppression of appetite and preserving or preservation of muscle during weight loss in a subject administered with Taurine.

[0087]

[0085] According some embodiments, NAT and Taurine are administered concurrently. In some embodiments, NAT and Taurine are administered sequentially.

[0088]

[0086] In one embodiment, it will be appreciated that NAT and Taurine according to the present invention can be provided to the subject with additional active agent(s) to achieve an improved therapeutic effect as compared to treatment with each agent by itself.

[0087] In some embodiments, an effective amount and / or a synergistically effective amount of NAT and Taurine is the amount of the mentioned herein NAT and Taurine necessary for the in vivo measurable expected biological effect The actual amount administered, and the rate and time course of administration, will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage, timing, etc., is within the responsibility of general practitioners or specialists, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of deliveiy, the method of administration and other factors known to practitioners. Examples of techniques and protocols can be found in Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins, Philadelphia, Pa., (2005). In some embodiments, preparation of effective amount or dose can be estimated initially from in vitro assays. In one embodiment, a dose can be formulated in animal models and such information can be used to more accurately determine useful doses in humans.

[0089]

[0088] The composition may include additional compounds that further enhance the synergistic effects of NAT and Taurine. For example, certain vitamins or minerals may be added to support the metabolic processes involved in appetite suppression and muscle preservation.

[0090]

[0089] In some embodiments, taurine helps maintain lean muscle mass during caloric restriction or weight loss (see Figs. 3A-3B). Taurine supports muscle function by regulating calcium homeostasis, reducing oxidative stress, and modulating protein synthesis pathways. These mechanisms help mitigate muscle breakdown that often occurs during weight loss.

[0091]

[0090] As used herein, the term "lean muscle” refers to a muscle being devoid of or comprising reduced amount of fat.

[0092]

[0091] According to another aspect there is provided a method for determining a subject is suitable and / or is in need of suppressing appetite and preserving muscle during weight loss. In some embodiments, the method comprises selecting a subject is suitable and / or is in need of suppressing appetite and preserving muscle during weight loss.

[0093]

[0092] The dosage of taurine in the composition ranges from about 500 mg to about 3000 mg per day. For example, a composition contains 500 mg of taurine to be administeredtwice daily, resulting in a total daily dose of 1000 mg. The specific dosage is adjusted based on factors such as body weight, age, and individual response to the compound.

[0094]

[0093] When combined with NAT, taurine offers synergistic effects. The presence of taurine in the composition slows the conversion of NAT via the phosphotriesterase-related (PTER) enzyme. This slowed conversion results in extended time of action for NAT, increasing its appetite-suppressing efficacy.

[0095]

[0094] In some embodiments, the combination of NAT and taurine provides benefits beyond appetite suppression and muscle preservation. Taurine supplementation supports cardiovascular health, improves insulin sensitivity, and enhances exercise performance. These additional effects contribute to overall metabolic health during weight loss.

[0096]

[0095] In some embodiments, the composition comprising NAT and taurine is coadministered with a GLP-1 receptor agonist In some embodiments, the GLP-1 receptor agonist is co-administered ata reduced dose(s) (compared to standalone or conventional GLP-1 receptor agonist therapy). In some embodiments, the co-administering at a reduced dose(s) comprises maintaining or enhancing efficacy of the GLP-1 receptor agonist. In some embodiments, the method comprises co-administering to the subject a composition comprising NAT and taurine and a GLP-1 receptor agonist In some embodiments, the method comprises administering to the subject a first composition comprising NAT and taurine and a second composition comprising a GLP-1 receptor agonist. In some embodiments, the method comprises administering to the subject a composition comprising NAT, taurine and a GLP-1 receptor agonist.

[0097]

[0096] In some embodiments, the composition comprising NAT and taurine is administered to a subject following discontinuation of GLP-1 receptor agonist therapy. In some embodiments, the NAT and taurine composition controls, reduces, inhibits, or any combination thereof, weight regain, such as by, but not restricted to, providing alternative appetite-suppression.

[0098]

[0097] In some embodiments, the composition comprising NAT and taurine is used for reducing hepatic fat accumulation. The composition is suitable for subjects with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). In some embodiments, the combination of NATand taurine reduces hepatic fat content, improves lipid metabolism, enhances insulin sensitivity, reduces hepatic lipogenesis, or any combination thereof.

[0099]

[0098] The composition is formulated to optimize the ratio of NAT to taurine. For example, a composition contains 500 mg of NAT and 500 mg of taurine in a single dose, to be taken twice daily. This formulation provides a total of 2 grams of taurine per day while using only 1 gram of NAT, reducing production costs while maintaining efficacy.

[0100]

[0099] In some embodiments, the composition is designed to provide a sustained release of both NAT and taurine. This sustained release helps maintain consistent levels of both compounds in the body, enhancing their effects on appetite suppression and muscle preservation throughout the day.

[0101]

[0100] The composition is administered through various routes, including oral, sublingual, or parenteral. In some embodiments, oral administration is preferred for convenience and patient compliance. The composition is formulated into tablets, capsules, powders, or liquid solutions for oral consumption.

[0102]

[0101] The composition includes N- Acetyltaurine (NAT) and taurine in various ratios and dosages to achieve optimal effects for appetite suppression and muscle preservation during weight loss. In some embodiments, the composition is formulated to provide a total daily dose of 2 grams of taurine while using only 1 gram of NAT.

[0103]

[0102] For example, the composition contains 500 mg of NAT and 500 mg of taurine in a single dose, to be administered twice daily. This formulation results in a total daily intake of 1 gram of NAT and 2 grams of taurine. The specific ratio of NAT to taurine is adjusted based on factors such as individual response, desired effects, and cost considerations.

[0104]

[0103] In some embodiments, the composition is designed to reduce the cost of goods sold (COGS) by lowering the amount of NAT relative to taurine. This approach leverages the conversion of NAT to taurine in the body, allowing for a lower overall NAT dosage while maintaining efficacy.

[0105]

[0104] The composition is formulated in various forms for oral administration. For example, the NAT and taurine mixture is encapsulated in gelatin or vegetarian capsules. Alternatively, the composition is prepared as a powder for reconstitution with water orother beverages. In some embodiments, the composition is formulated as a chewable tablet or a sublingual tablet for rapid absorption.

[0106]

[0105] The specific formulation is tailored to optimize bioavailability and absorption of both NAT and taurine. For instance, the composition includes additional excipients or carriers to enhance solubility or promote sustained release. In some embodiments, the composition is designed with a pH-sensitive coating to target release in specific regions of the gastrointestinal tract

[0107]

[0106] Different formulations of the composition offer varying benefits. For example, a fast-acting formulation provides rapid appetite suppression for individuals seeking immediate effects. Conversely, a sustained-release formulation offers prolonged appetite control and muscle support throughout the day.

[0108]

[0107] The composition is also formulated to include other complementary ingredients that enhance its effects on appetite suppression and muscle preservation. For instance, the formulation incorporates vitamins, minerals, or other amino acids that support overall metabolic health during weight loss.

[0109]

[0108] The composition comprising a taurine derivative, such as N- Acetyltaurine (NAT), and taurine is formulated into various convenient and palatable forms to enhance user compliance and optimize delivery. In some embodiments, the composition is incorporated into shakes, protein bars, and other food-like products.

[0110]

[0109] Shakes provide a versatile and easily consumable form of the composition. The NAT and taurine mixture is blended with protein powders, such as whey, casein, or plantbased proteins, to create a nutritionally balanced shake. In some aspects, a single-serving shake contains 500 mg of NAT and 500 mg of taurine, along with 20-30 grams of protein. The shakes are flavored with natural or artificial sweeteners and include additional ingredients such as vitamins, minerals, or fiber to enhance their nutritional profile.

[0111]

[0110] Protein bars offer a convenient on-the-go option for consuming the NAT and taurine composition. These bars are formulated to provide a balanced macronutrient profile while delivering the desired dosage of NAT and taurine. For example, a protein bar contains 250 mg of NAT and 250 mg of taurine, with the full daily dose achieved by consuming two bars. The bars are available in various flavors and incorporate different protein sources to cater to diverse dietary preferences.

[0111] In some embodiments, the composition is incorporated into gel-like products or gummies. These formulations appeal to individuals who prefer a chewable format over traditional pills or powders. Each gummy or gel packet contains a standardized dose of NAT and taurine, allowing for easy portion control and dosage management.

[0112]

[0112] The composition is also formulated into ready-to-drink beverages. These premixed drinks contain the full daily dose of NAT and taurine, along with other beneficial ingredients such as electrolytes, vitamins, or amino acids. The beverages are designed for consumption before or after physical activity, or as a meal replacement option for individuals following a calorie-restricted diet

[0113]

[0113] In some embodiments, the composition is incorporated into functional food products such as nutrition cookies, energy balls, or fortified cereals. These products provide a more familiar and enjoyable way to consume the NAT and taurine mixture, improving adherence to the supplementation regimen.

[0114]

[0114] The composition is also formulated into dissolvable powder sachets or effervescent tablets. These formats allow users to easily add the NAT and taurine mixture to water or other beverages, providing flexibility in how and when the composition is consumed.

[0115]

[0115] In some embodiments, the composition is incorporated into novel delivery systems such as oral thin films or sublingual strips. These formats offer rapid absorption and convenience, enhancing the onset of appetite-suppressing effects.

[0116]

[0116] The various formulations are designed to mask any potential unpleasant tastes associated with NAT or taurine, improving palatability and user experience. In some embodiments, the composition is microencapsulated or coated to control release and further improve taste profiles.

[0117]

[0117] Different formulations are combined to create comprehensive supplementation systems. For example, a morning shake is paired with an afternoon protein bar and an evening gummy, allowing for distributed dosing throughout the day while providing variety in consumption methods.

[0118]

[0118] The diverse range of formulations and delivery methods allows for personalized approaches to supplementation, catering to individual preferences, lifestyles, and dietaryneeds. This flexibility contributes to improved adherence and enhances the overall effectiveness of the NAT and taurine composition for appetite suppression and muscle preservation during weight loss.

[0119]

[0119] In some embodiments, the composition is designed to allow for flexible dosing based on individual needs. For example, the NAT and taurine are provided in separate capsules or as a customizable powder blend, allowing users to adjust the ratio or dosage as needed under the guidance of a healthcare professional.

[0120]

[0120] The formulation is optimized to minimize potential side effects while maximizing efficacy. This involves careful selection of excipients, particle size control, or specific manufacturing processes to enhance tolerability and absorption of the active ingredients.

[0121]

[0121] The composition comprising N- Acetyltaurine (NAT) and taurine exhibits synergistic effects that enhance both appetite suppression and muscle preservation during weight loss. These synergistic interactions result from the complementary mechanisms of action of NAT and taurine, as well as their influence on each other's metabolism and bioavailability.

[0122]

[0122] In some embodiments, the presence of additional taurine in the composition slows the conversion of NAT via the phosphotriesterase-related (PTER) enzyme. This slowed conversion results in an extended time of action for NAT, increasing its appetitesuppressing efficacy. The prolonged presence of NAT in the body leads to more sustained appetite control throughout the day.

[0123]

[0123] The mechanism behind this interaction involves competitive inhibition or allosteric modulation of the PTER enzyme by taurine. By slowing the rate of NAT conversion, taurine effectively increases the half-life of NAT in the body, allowing for more consistent and prolonged appetite suppression effects.

[0124]

[0124] In some embodiments, the extended time of action of NAT due to the presence of taurine results in improved weight loss outcomes. For example, individuals taking the NAT -taurine composition experience reduced food cravings and lower caloric intake over a longer period compared to those taking NAT alone.

[0125]

[0125] The synergistic effects of NAT and taurine also extend to muscle preservation. While NAT primarily functions as an appetite suppressant, its gradual conversion totaurine contributes to the muscle-sparing effects of the composition. The additional taurine supplementation further enhances these effects by providing a more consistent supply of taurine to support muscle function and protein synthesis during weight loss.

[0126]

[0126] In some embodiments, the combination of NAT and taurine leads to improved body composition outcomes compared to either compound alone. For example, individuals using the NAT-taurine composition experience greater fat loss while maintaining more lean muscle mass compared to those using traditional appetite suppressants or following calorie-restricted diets without supplementation.

[0127]

[0127] The synergistic effects of NAT and taurine also influence metabolic parameters. In some embodiments, the composition leads to improved insulin sensitivity and glucose metabolism, which further support weight loss efforts and overall metabolic health.

[0128]

[0128] The optimal ratio of NAT to taurine in the composition varies depending on individual factors and desired outcomes. In some embodiments, adjusting the ratio allows for fine-tuning of the balance between appetite suppression and muscle preservation effects. For example, a higher proportion of taurine relative to NAT is beneficial for individuals prioritizing muscle retention during weight loss.

[0129]

[0129] In some embodiments, the synergistic effects of NAT and taurine extend beyond weight loss and muscle preservation. The composition offers additional benefits such as improved exercise performance, enhanced recovery from physical activity, and better overall energy levels during calorie restriction.

[0130]

[0130] The synergistic effects of NAT and taurine highlight the importance of considering the interactions between components in multi-ingredient compositions for weight management. Further research is warranted to fully elucidate the mechanisms behind these synergistic effects and to optimize the composition for maximum efficacy in appetite suppression and muscle preservation during weight loss.

[0131]

[0131] The composition comprising N- Acetyl taurine (NAT) and taurine is administered through various methods to accommodate individual preferences and optimize efficacy. In some embodiments, the composition is formulated as oral supplements, powders, or other forms for convenient consumption.

[0132] Oral supplements include capsules, tablets, or softgels containing pre-measured amounts of NAT and taurine. For example, a single capsule contains 500 mg of NAT and 500 mg of taurine. In some embodiments, the oral supplements are designed for twice-daily administration, with one capsule taken in the morning and another in the evening.

[0132]

[0133] Powdered formulations allow for more flexible dosing. The composition is provided as a powder blend that is mixed with water or other beverages. In some embodiments, a single serving of the powder contains 500 mg of NAT and 500 mg of taurine. Users adjust the dosage by measuring different amounts of powder based on their individual needs and healthcare provider recommendations.

[0133]

[0134] Liquid formulations offer an alternative for individuals who have difficulty swallowing pills or prefer a more readily absorbable form. The composition is prepared as a concentrated liquid that is diluted with water or taken directly. In some embodiments, a 5 mL serving of the liquid contains 500 mg of NAT and 500 mg of taurine.

[0134]

[0135] Sublingual tablets or sprays provide a route for rapid absorption. These formulations allow the NAT and taurine to be absorbed directly into the bloodstream through the tissues under the tongue, leading to faster onset of effects. In some embodiments, sublingual formulations contain lower doses per administration but are taken more frequently throughout the day.

[0135]

[0136] The dosing schedule for the composition varies based on individual needs, body weight, and response to the treatment A common dosing regimen involves taking the composition twice daily, such as once in the morning and once in the evening. For example, an individual takes 500 mg of NAT and 500 mg of taurine in the morning, and repeats the same dose in the evening, resulting in a total daily intake of 1 gram of NAT and 2 grams of taurine.

[0136]

[0137] In some embodiments, the dosing schedule is adjusted to target specific times of day when appetite suppression is most beneficial. For instance, some individuals benefit from taking a dose 30 minutes before meals to help reduce food intake during eating occasions.

[0137]

[0138] The composition is also formulated for sustained release, allowing for once-daily dosing. In this case, a single daily dose contains a higher amount of NAT and taurine,designed to release gradually over 24 hours. For example, a sustained-release formulation contains 1 gram of NAT and 2 grams of taurine in a single daily dose.

[0138]

[0139] Dosing variations are implemented based on individual factors such as body weight, age, or metabolic rate. In some embodiments, healthcare providers recommend starting with a lower dose and gradually increasing to the full recommended dose over time. This approach helps minimize potential side effects and allows for assessment of individual tolerance.

[0139]

[0140] The composition is taken with or without food, depending on individual preference and tolerability. In some embodiments, taking the composition with food helps reduce the potential for gastrointestinal discomfort. However, the absorption and efficacy of NAT and taurine are not significantly affected by food intake.

[0140]

[0141] For individuals engaging in regular exercise, the timing of administration is coordinated with workout schedules. In some embodiments, taking a dose of the composition before exercise helps support muscle function and recoveiy.

[0141]

[0142] The duration of administration varies depending on individual weight loss goals and response to the treatment. In some embodiments, the composition is used as part of a short-term weight loss program, while in others, it is incorporated into a long-term weight management strategy. Regular monitoring and adjustment of the dosing regimen under healthcare provider supervision helps optimize outcomes and ensure safety.

[0142]

[0143] The composition comprising N- Acetyltaurine (NAT) and taurine is modified to include additional components or varied in its formulation to enhance its effects on appetite suppression and muscle preservation during weight loss. These variations offer benefits for different individuals or specific weight loss goals.

[0143]

[0144] In some embodiments, the composition includes branched-chain amino acids (BCAAs) in addition to NAT and taurine. BCAAs, which consist of leucine, isoleucine, and valine, support muscle protein synthesis and reduce muscle breakdown during calorie restriction. The ratio of BCAAs in the composition is adjusted to optimize their effects. For example, a 2:1:1 ratio of leucine to isoleucine to valine is used, providing a balanced amino acid profile. Alternatively, a 4:1:1 ratio favoring leucine is employed, enhancing the anabolic effects of the composition.

[0145] The composition also incorporates creatine as an additional muscle-enhancing supplement Creatine helps increase muscle strength and power output during resistance training, supporting muscle preservation and growth during weight loss. In some embodiments, the composition includes 3-5 grams of creatine monohydrate per serving, to be taken alongside the NAT and taurine components.

[0144]

[0146] Whey protein is added to the composition to provide a readily absorbable source of complete protein. This addition supports muscle protein synthesis and aids in muscle recoveiy, particularly when combined with resistance training. The composition includes 20-30 grams of whey protein per serving, which is consumed before or after exercise sessions.

[0145]

[0147] In some embodiments, [3-Hydroxy [3-Methylbutyrate (HMB) is incorporated into the composition. HMB, a metabolite of leucine, helps reduce muscle protein breakdown and supports lean mass retention during calorie restriction. The composition includes 1-3 grams of HMB per serving, enhancing the muscle-preserving effects of NAT and taurine.

[0146]

[0148] The composition is formulated to include various combinations of these additional components. For example, a comprehensive muscle-preserving formulation combines NAT, taurine, BCAAs (in a 4:1:1 ratio favoring leucine), creatine, and HMB. This multiingredient approach offers synergistic benefits for individuals seeking to maximize muscle retention during weight loss.

[0147]

[0149] In some embodiments, the composition is designed with customizable options, allowing users to adjust the inclusion or dosage of specific components based on their individual needs or preferences. For instance, the NAT and taurine base is offered with optional add-ins of BCAAs, creatine, or HMB, which are selected based on specific fitness goals or dietary requirements.

[0148]

[0150] The timing of administration for these varied compositions is adjusted to optimize their effects. For example, a formulation including BCAAs and whey protein is consumed immediately before or after resistance training sessions to support muscle protein synthesis. Conversely, a composition focused on NAT, taurine, and creatine is taken at regular intervals throughout the day to maintain consistent appetite suppression and muscle support.

[0151] In some embodiments, the composition is formulated into separate products for different times of day. For instance, a morning formula emphasizes appetite suppression with higher NAT content, while an evening formula focuses on muscle preservation with increased taurine and BCAA content

[0149]

[0152] According to another aspect, there is provided a method for reducing or treating stress or a disorder associated therewith in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a NAT, taurine, and BHB-phenylalanine.

[0150]

[0153] According to another aspect, there is provided a method for reducing hepatic fat accumulation in a subject in need thereof. According to another aspect, there is provided a method for treating or preventing metabolic dysfunction-associated steatotic liver disease (MASLD) in a subject in need thereof. According to another aspect, the is provided a method for prolonging the half-life of N-acetyltaurine in a subject In some embodiments, the method comprises administering to the subject an effective amount a composition comprising a taurine derivative and taurine.

[0151]

[0154] In some embodiments, the taurine derivative and taurine are present in a weight ratio of 1:1, 1:2, 1:3, 1:4, OR 1:5. In some embodiments, the taurine derivative and taurine are present in a weight ratio ranging between of 1:1 and 1:5, 1:2 and 1:5, 1:3 and 1:5, or 1:4 and 1:5. Each possibility represents a separate embodiment of the invention.

[0152]

[0155] In some embodiments, the taurine derivative comprises ATA-Mg (magnesium salt of N-acetyltaurine).

[0153]

[0156] The variations and additional components in the composition allow for tailored approaches to weight loss and muscle preservation. These modifications address individual differences in metabolism, exercise habits, and weight loss goals, improving the overall efficacy of the composition for a broader range of users.

[0154]

[0157] A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the disclosure. Accordingly, other implementations are within the scope of the following claims.

[0158] Any concentration ranges, percentage range, or ratio range recited herein are to be understood to include concentrations, percentages or ratios of any integer within that range and fractions thereof, such as one tenth and one hundredth of an integer, unless otherwise indicated.

[0155]

[0159] Any number range recited herein relating to any physical feature, such as polymer subunits, size or thickness, are to be understood to include any integer within the recited range, unless otherwise indicated.

[0156]

[0160] As used herein, the terms "subject” or "individual” or "animal” or "patient” or "mammal,” refers to any subject, particularly a mammalian subject, for whom therapy is desired, for example, a human.

[0157]

[0161] In the discussion unless otherwise stated, adjectives such as "substantially” and "about” modifying a condition or relationship characteristic of a feature or features of an embodiment of the invention, are understood to mean that the condition or characteristic is defined to within tolerances that are acceptable for operation of the embodiment for an application for which it is intended. Unless otherwise indicated, the word "or” in the specification and claims is considered to be the inclusive "or” rather than the exclusive or, and indicates at least one of, or any combination of items it conjoins.

[0158]

[0162] It should be understood that the terms "a” and "an” as used above and elsewhere herein refer to "one or more” of the enumerated components. It will be clear to one of ordinary skill in the art that the use of the singular includes the plural unless specifically stated otherwise. Therefore, the terms "a”, "an” and "at least one” are used interchangeably in this application.

[0159]

[0163] For purposes of better understanding the present teachings and in no way limiting the scope of the teachings, unless otherwise indicated, all numbers expressing quantities, percentages or proportions, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term "about” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0164] As used herein, the term "about” refers to ±10%.

[0160]

[0165] In the description and claims of the present application, each of the verbs, "comprise”, "include”, and "have” and conjugates thereof, are used to indicate that the object or objects of the verb are not necessarily a complete listing of components, elements or parts of the subject or subjects of the verb.

[0161]

[0166] Other terms as usedherein are meantto be definedby their well-known meanings in the art.

[0162]

[0167] As used herein, the term "synergistically effective amount” refers to an amount of two or more compounds that, when administered together, produces an effect greater than the sum of the effects of each compound administered alone. In some embodiments, synergy is assessed using the Bliss independence model, wherein the expected combined effect is calculated as: rexp = rA + (1 - rA) x rB, where rA and rB are the fractional effects of compounds A and B alone. An observed effect (robs) greater than rexp indicates synergy.

[0163]

[0168] As used herein, the term "taurine derivative” refers to a compound derived from or structurally related to taurine (2-aminoethanesulfonic acid). Taurine derivatives include, but are not limited to, N-acetyltaurine (NAT), ATA-Mg (magnesium salt of N-acetyltaurine), and other N-acyl taurine derivatives wherein the amino group of taurine is acylated with an acyl group.

[0164]

[0169] As used herein, the term "PTER modulation” refers to any alteration in the activity, expression, or function of the phosphotriesterase-related protein (PTER) enzyme. PTER modulation includes inhibition of PTER-mediated hydrolysis of N-acetyltaurine, shifting the equilibrium of the PTER-catalyzed reaction toward N-acetyltaurine synthesis, or any other mechanism that affects the net conversion rate of N-acetyltaurine by PTER.

[0165]

[0170] As used herein, the term "GLP-1 receptor agonist” refers to a compound that binds to and activates the glucagon-like peptide- 1 (GLP-1) receptor. GLP-1 receptor agonists include, but are not limited to, semaglutide, liraglutide, tirzepatide, dulaglutide, exenatide, and lixisenatide.

[0166]

[0171] As used herein, the term "subject in need thereof’ refers to a subject who benefits from administration of the compositions or methods described herein. Subjects in needthereof include subjects who are overweight or obese, subjects seeking appetite suppression or weight loss, subjects seeking to preserve muscle mass during weight loss, subjects with sarcopenia, subjects with insulin resistance, subjects with metabolic dysfunction-associated steatotic liver disease (MASLD), subjects currently receiving GLP-1 receptor agonist therapy, or subjects who have discontinued GLP-1 receptor agonist therapy.

[0167]

[0172] As used herein, the term "sarcopenia" refers to a condition characterized by the progressive loss of skeletal muscle mass, strength, and function, typically associated with aging, chronic disease, or prolonged periods of physical inactivity. Symptoms associated with sarcopenia include, but are not limited to, reduced muscle strength, decreased physical performance, impaired mobility, increased risk of falls, and reduced quality of life.

[0168]

[0173] As used herein, the term "insulin resistance" refers to a condition in which cells in the body do not respond effectively to insulin, resulting in impaired glucose uptake and elevated blood glucose levels. Insulin resistance is associated with metabolic disorders including type 2 diabetes, metabolic syndrome, and obesity.

[0169]

[0174] As used herein, the term "glucose homeostatic levels" or "glucose homeostasis" refers to the maintenance of blood glucose concentrations within a normal physiological range, typically between about 70 mg / dL and about 100 mg / dL in a fasting state for humans.

[0170]

[0175] As used herein, the term "branched chain amino acid" or "BCAA" refers to the essential amino acids leucine, isoleucine, and valine, which are characterized by aliphatic side chains with a branch point.

[0171]

[0176] As used herein, the term "Hydroxy beta-methylbutyric acid" or "HMB" (also known as [3-Hydroxy p-methylbutyrate) refers to a metabolite of the amino acid leucine with the chemical formula C5H10O3. HMB is involved in protein metabolism and is associated with reduced muscle protein breakdown.

[0172]

[0177] As used herein, the term "anti-obesity drug" refers to a pharmacological agent used to reduce or control body weight. Anti-obesity drugs include, but are not limited to, GLP-1 receptor agonists (such as semaglutide, liraglutide, and tirzepatide), lipaseinhibitors (such as orlistat], and other agents that affect appetite, metabolism, or nutrient absorption.

[0173]

[0178] As used herein, the term "BHB-Phe" refers to beta-hydroxybutyrate conjugated to phenylalanine. BHB-Phe is a compound wherein beta-hydroxybutyrate (BHB), a ketone body, is covalently bound to the amino acid phenylalanine.

[0174]

[0179] As used herein, the terms “treatment” or “treating” of a disease, disorder, or condition encompasses alleviation of at least one symptom thereof, a reduction in the severity thereof, or inhibition of the progression thereof. Treatment need not mean that the disease, disorder, or condition is totally cured. To be an effective treatment, a useful composition herein needs only to reduce the severity of a disease, disorder, or condition, reduce the severity of symptoms associated therewith, or provide improvement to a patient or subject’s quality of life.

[0175]

[0180] As used herein, the term “prevention” of a disease, disorder, or condition encompasses the delay, prevention, suppression, or inhibition of the onset of a disease, disorder, or condition. As used in accordance with the presently described subject matter, the term "prevention" relates to a process of prophylaxis in which a subject is exposed to the presently described peptides prior to the induction or onset of the disease / disorder process. This could be done where an individual has a genetic pedigree indicating a predisposition toward occurrence of the disease / disorder to be prevented. For example, this might be true of an individual whose ancestors show a predisposition toward certain types of, for example, inflammatory disorders. The term "suppression" is used to describe a condition wherein the disease / disorder process has already begun but obvious symptoms of the condition have yet to be realized. Thus, the cells of an individual may have the disease / disorder, but no outside signs of the disease / disorder have yet been clinically recognized. In either case, the term prophylaxis can be applied to encompass both prevention and suppression. Conversely, the term "treatment" refers to the clinical application of active agents to combat an already existing condition whose clinical presentation has already been realized in a patient.

[0176]

[0181] In some embodiments, the method comprises selecting a subject in need of therapy, as disclosed herein.

[0177]

[0182] In some embodiments, the method comprises selecting a subject in need of prevention of insulin resistance and treating the subject according to the method of the invention.

[0183] In some embodiments, the method comprises selecting a subject in need of prevention of muscle loss during weight loss, wherein the subject is treated with a GLP-1 receptor agonist

[0178]

[0184] Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

[0179] EXAMPLES

[0180] EXAMPLE 1

[0181]

[0185] The inventors performed a study at Science in Action in Diet Induced Obese mice, as follows.

[0182]

[0186] 26-28-week male DIO C57BL / 6J mice, intraperitoneal administration, 14-day treatment, five arms (vehicle, BHB-Phe, NAT, BHB-Phe+NAT, NAT+Taurine). The results are presented in Fig. 1, and are as follows (including p-values):

[0183]

[0187] NAT alone: 66-68% weight gain reduction (p = 2.8xl0“3vs vehicle)

[0184]

[0188] BHB-Phe alone: 58% weight gain reduction (p = 5.9xl0“3vs vehicle)

[0185]

[0189] NAT + Taurine: 88% weight gain reduction (p = 2.1xl0“5vs vehicle)

[0186]

[0190] BHB-Phe + NAT: 104% weight gain reduction / net weight loss (p = 8.9xl0“4vs vehicle).

[0187] EXAMPLE 2

[0188]

[0191] A Bliss Independence Synergy Analysis (NAT+Taurine) was conducted. This is mathematical proof.

[0189]

[0192] r(NAT) = 0.68; r(Tau): tested via published literature comparator.

[0190]

[0193] Bliss expected if taurine-alone = 62.5%: r_exp = 0.68 + 0.32(0.625) = 0.88 = r_obs -> breakeven.

[0194] Published Wei et al. 2024 (Nature 633:182): taurine alone at matched 15 mg / kg / day IP = vehicle (p = NS), i.e., r(Tau) « 0

[0191]

[0195] Therefore: r_exp(Bliss, r_Tau=0) = 0.68 + 0 = 0.68; r_obs = 0.88; Ar = +0.20 — synergy confirmed.

[0192] EXAMPLE 3

[0193]

[0196] Metabolic blood markers, including glucose, triglycerides (TG), and cholesterol, were also quantified. Glucose -30% (p = 0.009), TG -25% (p = 0.001), and cholesterol -30% (p = 0.032), were observed for NAT+TAU (Figs.2A-2C, respectively). As previously described, taurine-alone at clinical doses achieves only 4-6% glucose and 7-10% TG reduction in humans (Nie et al., 2025, Nutrition Reviews) and was null for glucose according to Wei et al, 2024, Nature. As such, a 30% glucose reduction is not achievable by taurine alone, and therefore, synergy is confirmed.

[0194] EXAMPLE 4

[0195]

[0197] Further shown is that the treatment according to the invention allows preservation of muscle and does not impose an adverse effect to this extent. Muscle grip strength and hang- time measurements in NAT+TAU showed no significant decline vs vehicle (Figs. 3A-3B, respectively).

[0196] EXAMPLE 5

[0197]

[0198] The following anecdotal human use data and investigator self-experiment CGM data are provided as hypothesis-generating observations consistent with the proposed mechanism of action. These data are not controlled clinical studies and are not intended to constitute proof of efficacy.

[0198] Anecdotal User Reports

[0199]

[0199] Four subjects received NATLean demo bottles containing ATA-Mg 750 mg and Taurine 1,650 mgper day, administered orally as three capsules daily (standard regimen: 2 capsules in the morning, 1 in the evening). No BHB-Phe was included. Subjects included: SP, a female former GLP-1 receptor agonist user who had recently discontinued therapy; GL, a 36-year-old female concurrently on Metformin; A.I., a 55-year-old male onMetformin with a history of GLP-1 failure (no weight loss achieved on semaglutide); and O.S., a post-GLP-1 rebounder who had regained weight following discontinuation of GLP-1 therapy.

[0200]

[0200] Among the three subjects with prior GLP-1 exposure (SP, A.I., O.S.), appetite suppression was reported within the first two weeks of use. SP reported prolonged satiety, an energy boost, and loss of 6 lbs over approximately two weeks, noting the absence of nausea or GI side effects in contrast to her prior GLP-1 experience. O.S. reported reduced hunger. A.I. reported effective appetite suppression following dose adjustment from a single morning dose to a split regimen (2 capsules AM, 1 capsule PM), which resolved initial GI symptoms; this subject represents a GLP-1 failure phenotype in whom NATLean produced appetite suppression where GLP-1 therapy had not GL, a Metformin user without prior GLP-1 exposure, reported no effect on a prior trial of ATA-Mg alone; upon switching to the NAT+Taurine combination formula she reported elimination of snack cravings, prolonged satiety, and loss of approximately 2 kg. A fourth subject (MW), GLP-l-naive, reported delayed onset of appetite suppression and mealskipping behavior emerging toward the end of the first bottle with 3 lbs lost, consistent with a proposed cumulative threshold-dependent mechanism in subjects without prior GLP-1 priming of GFRAL circuitiy.

[0201] Investigator CGM Signal

[0202]

[0201] A 62-year-old male subject (BMI approximately 26, HbAlc 5.7%, fasting glucose 91 mg / dL) self-administered ATA-Mg 750 mg and Taurine 1,600 mg orally once daily with breakfast for approximately 3 months. This represents approximately 75% of the commercial NAT dose and 80% of the commercial Taurine dose, administered as a single morning bolus without an evening dose. The subject wore a FreeStyle Libre continuous glucose monitor (CGM) for 10 days (785 readings atl5-minute intervals). Net weight loss over the 3-month period was 2.5-3.0 kg, sustained as a stable plateau with no rebound, consistent with a set-point shift rather than caloric restriction. CGM analysis demonstrated zero new glucose-elevation events initiated during the 22:00-06:00 window across all 10 monitored nights, indicating complete suppression of nocturnal hedonic eating. Preserved homeostatic daytime eating (1-2 structured postprandial excursions per day) was confirmed. The dissociation between preserved homeostatic feeding and abolished hedonic feeding is the predicted behavioral signature ofGFRAL / area postrema pathway activity. Post-dose kinetics (09:15-11:30) showed mean glucose 92.9 mg / dL with no hypoglycemic events, inconsistent with a GLP-1 secretagogue mechanism and consistent with PTER-mediated brainstem signaling. These observations occurred at sub-commercial dose with no evening coverage, representing a conservative lower bound for the commercial BID formulation.

[0203] BID Dosing Rationale for Post-GLP-1 Indication

[0204]

[0202] The QD CGM data in ‘Investigator CGM Signal’ described above’ demonstrates that a single morning dose produced complete nocturnal hedonic suppression 12-16 hours post-dose, suggesting a tonic GFRAL signaling duration that outlasts the pharmacokinetic half-life of NAT. However, in subjects within 1-4 weeks of GLP-1 receptor agonist discontinuation, pharmacologically-driven ghrelin rebound creates a high-amplitude hedonic drive in the 19:00-23:00 window that may exceed what tonic daytime dosing sustains. Accordingly, an asymmetric BID regimen is proposed for the post-GLP-1 indication: 500 mg NAT + 1,000 mg Taurine with breakfast and 500 mg NAT + 1,000 mg Taurine with the evening meal (total daily: 1,000 mg NAT + 2,000 mg Taurine). This BID regimen provides reinforced GFRAL coverage during the high-risk evening hedonic window without increasing total daily dose relative to the commercial QD formulation. Triple Combination (NAT + Taurine + BHB-Phe)

[0205]

[0203] Without being bound by theory, the addition of BHB-Phe to the NAT+Taurine composition is expected to provide complementary and mechanistically distinct benefits beyond those of the binaiy combination. Preclinical data demonstrate that BHB-Phe produced weight reduction in diet-induced obese mice without a corresponding reduction in food intake, in contrast to NAT which produced weight reduction with reduced food intake. This dissociation suggests BHB-Phe operates through metabolic shunting and altered energy partitioning rather than appetite suppression, potentially involving HCAR2 (GPR109A)-mediated hypothalamic signaling, HDAC inhibition via the BHB backbone, and normalization of HPA axis tone. The triple combination (NAT + Taurine + BHB-Phe) is therefore expected to provide: (i) GFRAL-mediated appetite suppression and hedonic eating suppression from NAT+Taurine; (ii) metabolic shunting and energy repartitioning from BHB-Phe through a non-overlapping central mechanism; and (iii) potential additional anxiolytic and stress-normalizing activity relevant to thepost-GLP-1 discontinuation population, in whom elevated ghrelin and psychological stress may compound hedonic rebound.

[0206]

[0204] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments unless the embodiment is inoperative without those elements.

Claims

CLAIMS1. A composition, comprising a synergistically effective amount of taurine derivative and taurine.

2. The composition of claim 1, wherein the composition is administered in a dosage of 250 to 1,000 mg NAT and 250 to 2,000 mg taurine twice daily.

3. The composition of claim 1 or 2, wherein the composition is administered in a dosage of 400 to 600 mg NAT and 800 to 1,000 mg taurine twice daily.

4. The composition of claim 2 or 3, wherein a first administration is with a breakfast meal, and a second administration is with an evening meal.

5. The composition of any one of claims 1 to 4, being characterized by a prolonged appetite-suppressing effect of said taurine derivative.

6. The composition of any one of claims 1 to 5, being characterized by enhanced efficacy of said taurine derivative for appetite suppression compared to said taurine derivative alone.

7. The composition of any one of claims 1 to 6, being characterized by supporting lean muscle mass preservation during weight loss.

8. The composition of any one of claims 1 to 7, used in a method for appetite suppression and muscle preservation during weight loss in a subject administered therewith.

9. The composition of claim 8, wherein said subject is administered with a total daily taurine amount of 1.5-4 grams.

10. The composition of claim 8 or 9, wherein said composition is administered with a reduced dosage of said taurine derivative compared to administration of said taurine derivative alone.

11. The composition of any one of claims 1 to 10, wherein said taurine derivative comprises N- Acetyltaurine (NAT).

12. The composition of any one of claims 1 to 11, further comprising beta hydroxybutyrate (BHB) conjugated to phenylalanine (BHB-Phe)13. A method for suppressing appetite and preserving muscle during weight loss in a subject in need thereof, the method comprising administering to a subject a composition comprising taurine derivative and taurine, thereby suppressing appetite and preserving muscle during weight loss in the subject14. The method of claim 13, wherein said muscle is lean muscle.

15. A method for treating sarcopenia or ameliorating at least one symptom associated therewith in a subject in need thereof, the method comprising administering to a subject a composition comprising taurine derivative and taurine, thereby treating sarcopenia or ameliorating at least one symptom associated therewith in the subject.

16. A method for treating or preventing insulin resistance in a subject in need thereof, the method comprising administering to a subject a composition comprising taurine derivative and taurine, thereby treating or preventing insulin resistance in the subject17. The method of claim 16, wherein said treating comprises restoring glucose homeostatic levels in said subject18. The method of any one of claims 13 to 16, wherein said administering is in a dosage ranging between 250 and 1,000 mg of said taurine derivative and ranging between 250 and 2,000 mg taurine, twice daily.

19. The method of any one of claims 13 to 17, wherein said administering is in a dosage ranging between 400 and 600 mg of said taurine derivative and 800 to 1,000 mg taurine, twice daily.

20. The method of claim 18 or 19, wherein a first administration is with a breakfast meal, and a second administration is with an evening meal.

21. The method of any one of claims 15 to 20, wherein said administering is ata total daily taurine amount ranging between 1.5 and 4 grams.

22. The method of any one of claims 15 to 21, wherein said administering is at a reduced dosage of said taurine derivative compared to said taurine derivative being administered alone.

23. The method of any one of claims 15 to 22, wherein said suppressing appetite and preserving muscle during weight loss comprises prolonging an appetite-suppressing effect of said taurine derivative.

24. The method of any one of claims 15 to 23, wherein said composition is characterized by enhanced efficacy of said taurine derivative for appetite suppression compared to administration of said taurine derivative alone.

25. The method of any one of claims 15 to 24, wherein said composition further comprises a branched chain amino acid (BCAA), Hydroxy beta-methyl butyric acid (hmb), creatine, or any combination thereof.

26. The method of any one of claims 15 to 25, wherein said administering further comprises administering to said subject a therapeutically effective amount of an antiobesity drug.

27. The method of claim 26, wherein said anti-obesity drug comprises a GLP-1 agonist.

28. The method of claim 26, wherein said anti-obesity drug is selected from the group consisting of: semaglutide, orlistat, metformin, and any combination thereof.

29. The method of any one of claims 26 to 28, wherein said composition and said antiobesity drug are co-administered in a synergistically effective amount.

30. The method of any one of claims 15 to 29, wherein any one of said suppressing, treating, preventing, and ameliorating, comprises inhibiting phosphotriesterase-related enzyme (PTER)-mediated conversion of said taurine derivative, thereby prolonging an effect of said taurine derivative.

31. The method of claim 30, wherein said effect is appetite-suppressing effect.

32. The method of any one of claims 15 to 31, wherein said taurine derivative is NAT.

33. A method for prolonging the appetite-suppressing effect of a taurine derivative in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of a composition comprising taurine and a taurine derivative.

34. The method of claim 33, wherein said prolonging of said appetite-suppressing effect comprises modulating enzymatic conversion of said taurine derivative by PTER in said subject.

35. A method for managing weight regain following discontinuation of a GLP-1 receptor agonist therapy in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of a composition comprising a taurine derivative and taurine.

36. A method for augmenting weight loss while being treated with a GLP-1 receptor agonist in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of a composition comprising a taurine derivative and taurine.

37. A method for treating or preventing muscle loss during weight loss in a subject beingtreated with a GLP-1 receptor agonist, the method comprising administering to said subject a therapeutically effective amount of a composition comprising a taurine derivative and taurine.

38. The method of any one of claims 33 to 37, wherein said taurine derivative is NAT.